Tapering Heart Failure Medication in Patients with Heart Failure with Recovered Ejection Fraction; Open Label Prospective Random Trial
NCT ID: NCT06724653
Last Updated: 2024-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
150 participants
INTERVENTIONAL
2025-12-06
2027-11-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Drug tapering group is 2 groups, which one is RAS blocker tapering group and others is beta blocker tapering group.
Drug tapering group is monitored ejection fraction, LV dimension and LV GLS by 1-3 month.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RAS blocker tapering arm
RAS blocker tapering
RAS blocker tapering group
RAS blocker tapering out
Beta blocker tapering out
Beta blocker tapering out group
Beta blocker tapering arm
Beta blocker tapering arm
RAS blocker tapering group
RAS blocker tapering out
Beta blocker tapering out
Beta blocker tapering out group
Control
Drug maintain group
RAS blocker tapering group
RAS blocker tapering out
Beta blocker tapering out
Beta blocker tapering out group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RAS blocker tapering group
RAS blocker tapering out
Beta blocker tapering out
Beta blocker tapering out group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* follow up echocardiogram ejection fraction over 50% and LVEDD index normal range
* NTprobnp criteria
1. eGFR ≥60 ; less 440
2. eGFR 45-59: less 980
3. eGFR 30-44; less 1220
4. eGFR \< 30 : less 5300
5. in HD; no criteria for NTproBNP
* on more than 3 heart failure medication ( RAS blocker, beta blocker, mineral corticoid receptor antagonist, SGLT 2 inhibitor)
Exclusion Criteria
2. uncontrolled BP ( over 150/90)
3. coronary revascularization within 6 months
4. significant valve disease
5. arrhythmia requiring rate control
6. CKD with albuminuria ( over 30mg/g)
7. Pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chungnam National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-09-039-002
Identifier Type: OTHER
Identifier Source: secondary_id
IRB 2024-09-039-002
Identifier Type: -
Identifier Source: org_study_id